{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:43:14Z","timestamp":1763037794359,"version":"3.41.0"},"reference-count":101,"publisher":"Scientific Scholar","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>The WHO emergency use-listed (EUL) COVID-19 vaccines were developed against early strains of SARS-CoV-2. With the emergence of SARS-CoV-2 variants of concern (VOCs) - Alpha, Beta, Gamma, Delta and Omicron, it is necessary to assess the neutralizing activity of these vaccines against the VOCs. PubMed and preprint platforms were searched for literature on neutralizing activity of serum from WHO EUL vaccine recipients, against the VOCs, using appropriate search terms till November 30, 2021. Our search yielded 91 studies meeting the inclusion criteria. The analysis revealed a drop of 0-8.9-fold against Alpha variant, 0.3-42.4-fold against Beta variant, 0-13.8-fold against Gamma variant and 1.35-20-fold against Delta variant in neutralization titres of serum from the WHO EUL COVID-19 vaccine recipients, as compared to early SARS-CoV-2 isolates. The wide range of variability was due to differences in the choice of virus strains selected for neutralization assays (pseudovirus or live virus), timing of serum sample collection after the final dose of vaccine (day 0 to 8 months) and sample size (ranging from 5 to 470 vaccinees). The reasons for this variation have been discussed and the possible way forward to have uniformity across neutralization assays in different laboratories have been described, which will generate reliable data. Though <jats:italic toggle=\"yes\">in vitro<\/jats:italic> neutralization studies are a valuable tool to estimate the performance of vaccines against the backdrop of emerging variants, the results must be interpreted with caution and corroborated with field-effectiveness studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_2544_21","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T09:27:13Z","timestamp":1659432433000},"page":"105-122","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Neutralization assays for SARS-CoV-2"],"prefix":"10.25259","volume":"155","author":[{"given":"Labanya","family":"Mukhopadhyay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nivedita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pragya D.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"R2-17-20241212","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"R8-17-20241212","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of anrAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine:An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"R9-17-20241212","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26. COV2. S COVID-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-17-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17268\/rmt.2020.v16i01.01","article-title":"SARS-COV-2 variants","volume":"16","author":"Huam\u00e1n Saavedra","year":"2021","journal-title":"Rev M\u00e9dica Trujillo"},{"key":"R12-17-20241212","first-page":"1","article-title":"Investigation of novel SARS-CoV-2 variant Variant of Concern 202012 \/ 01 Technical briefing 2:Nomenclature of variants in the UK Current epidemiological findings","volume":"70","author":"Nell","year":"2020","journal-title":"Public Heal Engl"},{"key":"R15-17-20241212","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/microorganisms9071542","article-title":"SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India","volume":"9","author":"Cherian","year":"2021","journal-title":"Microorganisms"},{"key":"R16-17-20241212","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"R17-17-20241212","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2013Preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-17-20241212","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2:A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"R19-17-20241212","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152:Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R20-17-20241212","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations:Two open, non-randomised phase \u00bdstudies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"R21-17-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"R22-17-20241212","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV:A randomised, double-blind, placebo-controlled, phase \u00bdtrial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R24-17-20241212","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines:Knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"Heinz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"R26-17-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"R27-17-20241212","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement:An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R30-17-20241212","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum neutralizing activity elicited by mRNA-1273 vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med"},{"key":"R33-17-20241212","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"R35-17-20241212","doi-asserted-by":"crossref","first-page":"e0069621","DOI":"10.1128\/mBio.00696-21","article-title":"Convalescent-phase sera and vaccine-elicited antibodies largely maintain neutralizing titer against global SARS-CoV-2 variant spikes","volume":"12","author":"Tada","year":"2021","journal-title":"mBio"},{"key":"R36-17-20241212","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing activity of BNT162b2-elicited serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"R37-17-20241212","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3390\/v13061135","article-title":"Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals","volume":"13","author":"Trinit\u00e9","year":"2021","journal-title":"Viruses"},{"key":"R38-17-20241212","doi-asserted-by":"crossref","first-page":"103341","DOI":"10.1016\/j.isci.2021.103341","article-title":"Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera","volume":"24","author":"Tada","year":"2021","journal-title":"iScience"},{"key":"R39-17-20241212","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"R40-17-20241212","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMc2106083","article-title":"BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants","volume":"385","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"R41-17-20241212","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.3390\/v13122485","article-title":"SARS-CoV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity","volume":"13","author":"Neerukonda","year":"2021","journal-title":"Viruses"},{"key":"R42-17-20241212","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","article-title":"Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera","volume":"27","author":"Xie","year":"2021","journal-title":"Nat Med"},{"key":"R43-17-20241212","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"key":"R45-17-20241212","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"R46-17-20241212","doi-asserted-by":"crossref","first-page":"eabj5365","DOI":"10.1126\/sciadv.abj5365","article-title":"Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination","volume":"7","author":"Caniels","year":"2021","journal-title":"Sci Adv"},{"key":"R47-17-20241212","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41467-021-24285-4","article-title":"COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants","volume":"12","author":"Jalkanen","year":"2021","journal-title":"Nat Commun"},{"key":"R48-17-20241212","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3390\/v13102011","article-title":"Neutralization of SARS-CoV-2 variants by serum from BNT162b2 vaccine recipients","volume":"13","author":"Valleriani","year":"2021","journal-title":"Viruses"},{"key":"R49-17-20241212","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat Med"},{"key":"R50-17-20241212","first-page":"1","article-title":"Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccination in health care workers, Israel","volume":"5","author":"Lustig","year":"2021","journal-title":"Euro Surveill"},{"key":"R52-17-20241212","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/ciab492","article-title":"Neutralization Heterogeneity of UK and South African severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in BNT162b2-vaccinated or convalescent coronavirus disease 2019 (COVID-19) healthcare workers","volume":"74","author":"Marot","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R53-17-20241212","doi-asserted-by":"crossref","first-page":"eabj1750","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"key":"R54-17-20241212","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1080\/22221751.2021.2004866","article-title":"SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response","volume":"10","author":"Mileto","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"R55-17-20241212","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1038\/s41467-021-25167-5","article-title":"Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern","volume":"12","author":"Skelly","year":"2021","journal-title":"Nat Commun"},{"key":"R56-17-20241212","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/22221751.2021.1940305","article-title":"Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants","volume":"10","author":"Zani","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"R57-17-20241212","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1080\/22221751.2021.1945423","article-title":"Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I\/501Y. V1 and 20H\/501Y. V2 isolates of SARS-CoV-2","volume":"10","author":"Saade","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"R58-17-20241212","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"R59-17-20241212","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"Lancet"},{"key":"R61-17-20241212","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/s41467-021-25479-6","article-title":"Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum","volume":"12","author":"Bates","year":"2021","journal-title":"Nat Commun"},{"key":"R62-17-20241212","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/vaccines9050517","article-title":"Neutralizing antibody response of vaccinees to SARS-CoV-2 variants","volume":"9","author":"Anichini","year":"2021","journal-title":"Vaccines (Basel"},{"key":"R63-17-20241212","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jinf.2021.07.019","article-title":"Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected","volume":"83","author":"Gidari","year":"2021","journal-title":"J Infect"},{"key":"R64-17-20241212","doi-asserted-by":"crossref","first-page":"2101059","DOI":"10.2807\/1560-7917.ES.2021.26.49.2101059","article-title":"Neutralisation of the SARS-CoV-2 Delta sub-lineage AY.4.2 and B.1.617.2 +E484K by BNT162b2 mRNA vaccine-elicited sera, Denmark, 1 to 26 November 2021","volume":"26","author":"Lassauni\u00e8re","year":"2021","journal-title":"Euro Surveill"},{"key":"R65-17-20241212","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0140-6736(21)01854-7","article-title":"Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients","volume":"398","author":"Carr","year":"2021","journal-title":"Lancet"},{"key":"R66-17-20241212","doi-asserted-by":"crossref","first-page":"109825","DOI":"10.1016\/j.celrep.2021.109825","article-title":"B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination","volume":"37","author":"Arora","year":"2021","journal-title":"Cell Rep"},{"key":"R67-17-20241212","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"R70-17-20241212","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"R71-17-20241212","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"R72-17-20241212","first-page":"1327","article-title":"Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-\u03b1inhibitors","volume":"2","author":"Chen","year":"2021","journal-title":"Med Med (NY"},{"key":"R73-17-20241212","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"R74-17-20241212","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"R75-17-20241212","first-page":"896","article-title":"BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects","volume":"11","author":"Vicenti","year":"2021","journal-title":"Life (Basel"},{"key":"R76-17-20241212","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"R77-17-20241212","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-021-03693-y","article-title":"BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants","volume":"596","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"R78-17-20241212","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMc2107799","article-title":"Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants","volume":"385","author":"Edara","year":"2021","journal-title":"N Engl J Med"},{"key":"R79-17-20241212","first-page":"529","article-title":"SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines","volume":"29","author":"Shen","year":"2021","journal-title":"Cell"},{"key":"R80-17-20241212","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"R81-17-20241212","doi-asserted-by":"crossref","first-page":"e0131321","DOI":"10.1128\/JVI.01313-21","article-title":"Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants","volume":"95","author":"Choi","year":"2021","journal-title":"J Virol"},{"key":"R82-17-20241212","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1001\/jama.2021.4388","article-title":"Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination","volume":"325","author":"Edara","year":"2021","journal-title":"JAMA"},{"key":"R83-17-20241212","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc2103740","article-title":"Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351","volume":"384","author":"Shen","year":"2021","journal-title":"N Engl J Med"},{"key":"R89-17-20241212","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3390\/v13091693","article-title":"Antibody-mediated neutralization of authentic SARS-CoV-2 b.1.617 variants harboring l452r and t478k\/|ne484q","volume":"13","author":"Wilhelm","year":"2021","journal-title":"Viruses"},{"key":"R90-17-20241212","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7):An exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"R91-17-20241212","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"R92-17-20241212","doi-asserted-by":"crossref","first-page":"taab119","DOI":"10.1093\/jtm\/taab119","article-title":"Neutralization of Delta variant with sera of CovishieldTM vaccinees and COVID-19-recovered vaccinated individuals","volume":"28","author":"Sapkal","year":"2021","journal-title":"J Travel Med"},{"key":"R93-17-20241212","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26. COV2. S vaccine against SARS-CoV-2 variants in humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"R95-17-20241212","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable humoral and cellular immune responses 8 months after Ad26. COV2. S vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N Engl J Med"},{"key":"R96-17-20241212","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1038\/s41467-021-24909-9","article-title":"Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants","volume":"12","author":"Ikegame","year":"2021","journal-title":"Nat Commun"},{"key":"R97-17-20241212","doi-asserted-by":"crossref","first-page":"e0344221","DOI":"10.1128\/mbio.03442-21","article-title":"Longitudinal study after sputnik V vaccination shows durable SARS-CoV-2 neutralizing antibodies and reduced viral variant escape over time","volume":"13","author":"Gonzalez Lopez Ledesma","year":"2022","journal-title":"mBio"},{"key":"R98-17-20241212","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/vaccines9070779","article-title":"Neutralizing activity of sera from sputnik v-vaccinated people against variants of concern (VOC:B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow endemic SARS-CoV-2 variants","volume":"9","author":"Gushchin","year":"2021","journal-title":"Vaccines"},{"key":"R99-17-20241212","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1056\/NEJMc2103022","article-title":"Susceptibility of circulating SARS-CoV-2 variants to neutralization","volume":"384","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"key":"R100-17-20241212","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1473-3099(21)00287-5","article-title":"Serum neutralising activity againstSARS-CoV-2 variants elicited by CoronaVac","volume":"21","author":"Chen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R102-17-20241212","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/jmv.27310","article-title":"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies","volume":"94","author":"Fern\u00e1ndez","year":"2022","journal-title":"J Med Virol"},{"key":"R103-17-20241212","doi-asserted-by":"crossref","first-page":"E527","DOI":"10.1016\/S2666-5247(21)00129-4","article-title":"Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine:An immunological study","volume":"2","author":"Souza","year":"2021","journal-title":"Lancet Microbe"},{"key":"R104-17-20241212","first-page":"1","article-title":"Inactivated COVID-19 vaccine BBV152\/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2","volume":"28","author":"Sapkal","year":"2021","journal-title":"Travel Med"},{"key":"R105-17-20241212","doi-asserted-by":"crossref","first-page":"taab104","DOI":"10.1093\/jtm\/taab104","article-title":"Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152\/Covaxin","volume":"28","author":"Yadav","year":"2021","journal-title":"J Travel Med"},{"key":"R106-17-20241212","doi-asserted-by":"crossref","first-page":"taab077","DOI":"10.1093\/jtm\/taab077","article-title":"Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine","volume":"28","author":"Sapkal","year":"2021","journal-title":"J Travel Med"},{"key":"R107-17-20241212","doi-asserted-by":"crossref","first-page":"taab154","DOI":"10.1093\/jtm\/taab154","article-title":"Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152","volume":"28","author":"Yadav","year":"2021","journal-title":"J Travel Med"},{"key":"R109-17-20241212","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-021-03693-y","article-title":"BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants","volume":"596","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"R112-17-20241212","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3390\/v13112177","article-title":"High individual heterogeneity of neutralizing activities against the original strain and nine different variants of sars-cov-2","volume":"13","author":"Jaafar","year":"2021","journal-title":"Viruses"},{"key":"R115-17-20241212","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1038\/s41467-021-23473-6","article-title":"Immune response to SARS-CoV-2 variants of concern in vaccinated individuals","volume":"12","author":"Becker","year":"2021","journal-title":"Nat Commun"},{"key":"R116-17-20241212","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41586-021-04085-y","article-title":"Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity","volume":"600","author":"Lucas","year":"2021","journal-title":"Nature"},{"key":"R117-17-20241212","doi-asserted-by":"crossref","first-page":"103626","DOI":"10.1016\/j.ebiom.2021.103626","article-title":"Evidence for retained spike-binding and neutralizing activity against emergingSARS-CoV-2variants in serum of COVID-19mRNA vaccine recipients","volume":"73","author":"Carre\u00f1o","year":"2021","journal-title":"EBioMedicine"},{"key":"R119-17-20241212","doi-asserted-by":"crossref","first-page":"102298","DOI":"10.1016\/j.isci.2021.102298","article-title":"Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation","volume":"24","author":"Ganneru","year":"2021","journal-title":"iScience"},{"key":"R120-17-20241212","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"R122-17-20241212","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.4269\/ajtmh.17-0948","article-title":"Virus reduction neutralization test:A single-cell imaging high-throughput virus neutralization assay for dengue","volume":"99","author":"Whiteman","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"R123-17-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-017-0799-0","article-title":"Comparison of serological assays to titrate Hantaan and Seoul hantavirus-specific antibodies","volume":"14","author":"Li","year":"2017","journal-title":"Virol J"},{"key":"R124-17-20241212","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.7150\/ijbs.59184","article-title":"Construction and applications of SARS-CoV-2 pseudoviruses:A mini review","volume":"17","author":"Chen","year":"2021","journal-title":"Int J Biol Sci"},{"key":"R125-17-20241212","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/all.14893","article-title":"BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced","volume":"76","author":"Chang","year":"2021","journal-title":"Allergy"},{"key":"R126-17-20241212","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMc2104036","article-title":"Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2","volume":"384","author":"Lustig","year":"2021","journal-title":"N Engl J Med"},{"key":"R127-17-20241212","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","article-title":"SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans","volume":"595","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"R128-17-20241212","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"R129-17-20241212","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-021-04117-7","article-title":"Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants","volume":"600","author":"Andreano","year":"2021","journal-title":"Nature"},{"key":"R130-17-20241212","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41591-021-01347-0","article-title":"SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies","volume":"27","author":"Andreano","year":"2021","journal-title":"Nat Med"},{"key":"R132-17-20241212","doi-asserted-by":"crossref","first-page":"e72619","DOI":"10.7554\/eLife.72619","article-title":"mRNA vaccine-induced t cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status","volume":"10","author":"Neidleman","year":"2021","journal-title":"eLife"},{"key":"R133-17-20241212","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","article-title":"Impact of SARS-CoV-2 variants on the total CD4+and CD8+T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"R134-17-20241212","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41591-021-01347-0","article-title":"SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies","volume":"27","author":"Andreano","year":"2021","journal-title":"Nat Med"},{"key":"R136-17-20241212","doi-asserted-by":"crossref","first-page":"e02492","DOI":"10.1128\/mBio.02492-20","article-title":"Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 serum","volume":"12","author":"Oguntuyo","year":"2021","journal-title":"mBio"},{"key":"R137-17-20241212","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(21)00266-4","article-title":"WHO International Standard for evaluation of the antibody response to COVID-19 vaccines:call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2021","journal-title":"Lancet Microbe"},{"key":"R138-17-20241212","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.ijmr_2544_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:04:41Z","timestamp":1751497481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/neutralization-assays-for-sars-cov-2-implications-for-assessment-of-protective-efficacy-of-covid-19-vaccines\/"}},"subtitle":["Implications for assessment of protective efficacy of COVID-19 vaccines"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_2544_21","relation":{},"ISSN":["0971-5916"],"issn-type":[{"type":"print","value":"0971-5916"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}